Literature DB >> 33392962

Apoptosis Detection Methods in Diagnosis of Cancer and Their Potential Role in Treatment: Advantages and Disadvantages: a Review.

Amir Khodavirdipour1,2, Motahareh Piri3, Sarvin Jabbari1, Shiva Keshavarzi3, Reza Safaralizadeh1, Mohammad Yousef Alikhani4.   

Abstract

INTRODUCTION: Interruption of regulation of apoptosis can play a leading role in cancers where elevated apoptosis causes neurodegeneration, autoimmunity, AIDS, and ischemia. One famous example can be p53's downregulation, which is a tumor suppressor gene, which consequently can cause a decrease in apoptosis rate and intense tumor growth and progression and development and inactivation of 53; it can be extended to many cancers in human. Anyhow, apoptosis is a double-edge sword. There are many trials and studies are going on observation and understanding of different steps involved in apoptosis. Apoptosis has a very major role in carcinogenesis and the treatment of cancer. AIM: In this updated-cum-comprehensive review, we would like to cover what is apoptosis and cancer and also, will discuss all known methods of apoptosisdetection, their applicability in the treatment of cancer, and their advantages, disadvantages, and limitations.
MATERIAL AND METHODS: Published articles on indexing sources such as PubMed, Scopus from 2000 to date. RESULT: By considering all above information including each methods pros and cons, these routine methods could be great tool with distinctive qualities in treatmentwhich can be great help from patient perspective and as well from government ad health care system point of view.
CONCLUSION: Accurate diagnosis of cell apoptotic biopathways at different stages assists in evaluating near to exact apoptotic index, which is the perfect sign andindicator for metastasis and also prognosis, thus foreseeing treatment outcome.

Entities:  

Keywords:  Apoptosis; Apoptosis detection methods; Cancer treatment; Caspase; Flow cytometry; TEM

Year:  2021        PMID: 33392962     DOI: 10.1007/s12029-020-00576-9

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  67 in total

1.  Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.

Authors:  M Ocker; D Neureiter; M Lueders; S Zopf; M Ganslmayer; E G Hahn; C Herold; D Schuppan
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

2.  Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.

Authors:  J A Roth; D Nguyen; D D Lawrence; B L Kemp; C H Carrasco; D Z Ferson; W K Hong; R Komaki; J J Lee; J C Nesbitt; K M Pisters; J B Putnam; R Schea; D M Shin; G L Walsh; M M Dolormente; C I Han; F D Martin; N Yen; K Xu; L C Stephens; T J McDonnell; T Mukhopadhyay; D Cai
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

Review 3.  Novel agents for the treatment of chronic lymphocytic leukemia.

Authors:  Karim Abou-Nassar; Jennifer R Brown
Journal:  Clin Adv Hematol Oncol       Date:  2010-12

4.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

Authors:  Thomas M Rippin; Vladimir J N Bykov; Stefan M V Freund; Galina Selivanova; Klas G Wiman; Alan R Fersht
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

5.  XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer.

Authors:  Carolyn Cao; Yi Mu; Dennis E Hallahan; Bo Lu
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

6.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

Review 7.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

8.  Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

Authors:  J Kuball; M Schuler; E Antunes Ferreira; W Herr; M Neumann; L Obenauer-Kutner; L Westreich; C Huber; T Wölfel; M Theobald
Journal:  Gene Ther       Date:  2002-07       Impact factor: 5.250

9.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.

Authors:  Frank M Boeckler; Andreas C Joerger; Gaurav Jaggi; Trevor J Rutherford; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

10.  Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.

Authors:  Inge Marie Svane; Anders E Pedersen; Hans E Johnsen; Dorte Nielsen; Claus Kamby; Eva Gaarsdal; Kirsten Nikolajsen; Søren Buus; Mogens H Claesson
Journal:  Cancer Immunol Immunother       Date:  2004-02-25       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.